Supplemental material
Acta Oncologica
Volume 60, 2021 - Issue 11
ORIGINAL ARTICLES: CLINICAL ONCOLOGY
Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable
Johan Blakkisruda Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;b Department of Physics, University of Oslo, Oslo, NorwayCorrespondence[email protected]
https://orcid.org/0000-0002-0046-7327View further author information
https://orcid.org/0000-0002-0046-7327View further author information, , , , & Caroline Stokkea Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway;b Department of Physics, University of Oslo, Oslo, Norwayhttps://orcid.org/0000-0003-4465-9635View further author information
https://orcid.org/0000-0003-4465-9635View further author information